Optic Neuritis - Pipeline Review, H1 2020

April 2020 | 48 pages | ID: O520DFB2206EN
Global Markets Direct

Abstracts

Optic Neuritis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuritis - Pipeline Review, H1 2020, provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape.

Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon and flashing lights. Risk factors include age and genetic mutations.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuritis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 4 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Optic Neuritis - Overview
Optic Neuritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuritis - Companies Involved in Therapeutics Development
Bionure Farma SL
Commence Bio Inc
EnhanX Biopharm Inc
Japan Innovative Therapeutics Inc
Meta-IQ ApS
Mitochon Pharmaceuticals Inc
Noveome Biotherapeutics Inc
SanBio Inc
Optic Neuritis - Drug Profiles
BN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etomoxir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gypenoside - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Optic Neuritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Optic Neuritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuritis - Dormant Projects
Optic Neuritis - Discontinued Products
Optic Neuritis - Product Development Milestones
Featured News & Press Releases
May 15, 2019: Bionure appoints Dr. Lucia Septien as chief medical officer
May 09, 2019: Noveome Biotherapeutics announces publication of further preclinical results supporting the neuroprotective properties of ST266 in retinal ganglion cells
May 07, 2019: Neuroprotection Biotech Bionure Reports Successful Phase 1 Study for Lead Candidate BN201
Oct 09, 2018: Bionure appoints Dr. Laurent Nguyen as CEO
May 16, 2018: Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom
Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Optic Neuritis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Optic Neuritis - Pipeline by Bionure Farma SL, H1 2020
Optic Neuritis - Pipeline by Commence Bio Inc, H1 2020
Optic Neuritis - Pipeline by EnhanX Biopharm Inc, H1 2020
Optic Neuritis - Pipeline by Japan Innovative Therapeutics Inc, H1 2020
Optic Neuritis - Pipeline by Meta-IQ ApS, H1 2020
Optic Neuritis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2020
Optic Neuritis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
Optic Neuritis - Pipeline by SanBio Inc, H1 2020
Optic Neuritis - Dormant Projects, H1 2020
Optic Neuritis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Optic Neuritis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Bionure Farma SL
Commence Bio Inc
EnhanX Biopharm Inc
Japan Innovative Therapeutics Inc
Meta-IQ ApS
Mitochon Pharmaceuticals Inc
Noveome Biotherapeutics Inc
SanBio Inc